Gene · 3003
NIH grants2,103
NIH grants whose papers are about the gene, through NIH's grant-paper links.
721 to 740 of 2,103
Download this page as JSON| Grant | Title | GZMK papers | Newest fiscal year |
|---|---|---|---|
| R01CA168814 | Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease | 1 | 2024 |
| R01CA236074 | Intra- and inter-cellular signals that drive hepato-oncogenesis | 1 | 2024 |
| R01CA236814 | Novel NEK2 signaling pathways in myeloma progression | 1 | 2024 |
| R01CA236864 | DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | 1 | 2024 |
| R01CA239629 | Tumor-promoting liver injuries and mechanisms | 1 | 2024 |
| R01CA242020 | Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | 1 | 2024 |
| R01CA245005 | POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma | 1 | 2024 |
| R01CA245318 | Antigen-independent prediction and biomarker identification of cancer-specific T cells | 1 | 2024 |
| R01CA249210 | Role of MED1 in the AR-dependent transcription in advanced prostate cancer | 1 | 2024 |
| R01CA251599 | Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer | 1 | 2024 |
| R01CA252940 | Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | 1 | 2024 |
| R01CA262496 | Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML | 1 | 2024 |
| R01DA051906 | A Big Data Approach to Identify Epigenetic, Transcriptomic, and Network Dynamics as Immune Dysfunction Drivers Associated with HIV Infection and Substance Use Disorder | 1 | 2024 |
| R01DK067180 | Innate and adaptive immunity in celiac disease | 1 | 2024 |
| R01DK121805 | MiR-150 regulated adiose tissue B cells in obesity | 1 | 2024 |
| R01DK121929 | Beta cell extracellular vesicles in health and disease | 1 | 2024 |
| R01DK123749 | Decoding mutualistic microbiota-B cell interactions in the HIV-1-infected gut: impact on immunological non-responders | 1 | 2024 |
| R01DK124617 | Microbiota-mediated fibrotic remodeling in the inflamed intestine | 1 | 2024 |
| R01DK128320 | A new mechanism of hepatocyte proliferation under stress | 1 | 2024 |
| R01GM136886 | Experimental and bioinformatics platform for epigenome analysis using nanopore sequencing | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/grants?page=37